Oncopeptides AB (publ)

OM:ONCO BTA Stock Report

Market Cap: SEK 717.3m

Oncopeptides Valuation

Is ONCO BTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ONCO BTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ONCO BTA (SEK3) is trading below our estimate of fair value (SEK13.91)

Significantly Below Fair Value: ONCO BTA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ONCO BTA?

Key metric: As ONCO BTA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ONCO BTA. This is calculated by dividing ONCO BTA's market cap by their current revenue.
What is ONCO BTA's PS Ratio?
PS Ratio20.4x
SalesSEK 35.22m
Market CapSEK 717.26m

Price to Sales Ratio vs Peers

How does ONCO BTA's PS Ratio compare to its peers?

The above table shows the PS ratio for ONCO BTA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average28.5x
MVIR Medivir
45x66.2%SEK 316.3m
SANION Saniona
33.8x38.0%SEK 900.7m
ALZ Alzinova
17.9x17.7%SEK 312.1m
NICA Nanologica
17.2x95.5%SEK 151.1m
ONCO BTA Oncopeptides
20.4x57.7%SEK 717.3m

Price-To-Sales vs Peers: ONCO BTA is good value based on its Price-To-Sales Ratio (20.4x) compared to the peer average (28.4x).

Price to Sales Ratio vs Industry

How does ONCO BTA's PS Ratio compare vs other companies in the SE Biotechs Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
XBRANE Xbrane Biopharma
1.3x61.1%US$22.86m
SPRINT Sprint Bioscience
1.8x27.6%US$10.18m
LPGO Lipigon Pharmaceuticals
2.8x127.1%US$2.31m
GEAN Genetic Analysis
1.3xn/aUS$2.20m
ONCO BTA 20.4xIndustry Avg. 13.1xNo. of Companies8PS01224364860+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ONCO BTA is expensive based on its Price-To-Sales Ratio (20.4x) compared to the Swedish Biotechs industry average (10.5x).

Price to Sales Ratio vs Fair Ratio

What is ONCO BTA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ONCO BTA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio20.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ONCO BTA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/15 23:58
End of Day Share Price 2024/05/13 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncopeptides AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik HultgårdCarnegie Investment Bank AB
Patrik LingDNB Markets
Robert BurnsH.C. Wainwright & Co.